Tirzepatide Compared to Dulaglutide or Semaglutide for Major Heart Problems in Type 2 Diabetes with Heart Disease

Duality of Interest. J.W.O. has served on advisory boards or had speaker engagements with Corcept Therapeutics and Bayer AG. S.J.C. reports having a spouse employed by Depuy Synthes. B.M.E. reports grants (site coinvestigator) and personal fees (end point adjudication) from Novo Nordisk, a grant to Brigham and Women’s Hospital (principal investigator), and personal fees from Kowa not clearly relevant to the work; personal fees from Ipsen Pharmaceuticals for consulting and from NIDDK outside the submitted work; and consulting fees (editorial board member) from American Heart Association journal Circulation and royalties for peer review of UptoDate articles. R.J.G. reports grants from Amarin, Kowa, and Novartis (to employer) outside the submitted work. D.J.W. has served on data monitoring committees for Amgen. E.P. reports research grants to Brigham and Women’s Hospital (principal investigator) from Boehringer Ingelheim, AstraZeneca, and Bayer unrelated to the submitted work and receives royalties from UpToDate. No other potential conflicts of interest relevant to this article were reported.